Medicine Overview

Adult Dose
Clinical InformationAdministration Information
Indication: Anemia of Chronic Kidney Disease
Age: Adult
Condition: On dialysis for greater than or equal to 4 months, not treated with an erythropoietin-stimulating agent, pretreatment hemoglobin less than 9 g/dL
Dose: Tablet – 4 mg
Frequency: once daily
Note: Administer by mouth. Individualize dosing and use lowest dose sufficient to reduce need for red blood cell transfusions. Do not target a hemoglobin greater than 11 g/dL.
Indication: Anemia of Chronic Kidney Disease
Age: Adult
Condition: On dialysis for greater than or equal to 4 months, not treated with an erythropoietin-stimulating agent, pretreatment hemoglobin 9-10 g/dL
Dose: Tablet – 2 mg
Frequency: once daily
Note: Administer by mouth. Individualize dosing and use lowest dose sufficient to reduce need for red blood cell transfusions. Do not target a hemoglobin greater than 11 g/dL.

Child Dose
Clinical InformationAdministration Information
Age: Child
Dose: No approved pediatric dosage available
Note: No approved pediatric dosage available

Renal Dose
Clinical InformationAdministration Information
Condition: Renal impairment
Dose: Tablet – Dosage not provided
Note: Steady-state exposure of daprodustat is similar in patients with normal renal function and those with varying degrees of renal impairment. Systemic exposure of daprodustat metabolites was higher in patients with Stage 3 to 5 chronic kidney disease than in those with normal renal function.
Condition: Hemodialysis or peritoneal dialysis
Dose: Tablet – Dosage not provided
Note: Daprodustat exposure not significantly impacted. Exposures of metabolites were higher on non-dialysis days than on dialysis days.
Administration

Administer daprodustat orally once daily, with or without food, and without regard to the timing of dialysis or the concomitant administration of iron or phosphate binders. The tablets must be swallowed whole and should not be cut, crushed, or chewed. The starting dosage is individualized based on pre-treatment hemoglobin levels or previous erythropoiesis-stimulating agent (ESA) doses. Following initiation or dose modification, monitor hemoglobin every 2 weeks for the first month. Dose adjustments should occur no more than once every 4 weeks. In patients with moderate hepatic impairment, reduce the starting dose by half, except for the 1 mg dose. Safety and effectiveness have not been established in pediatric patients.

Side Effect

Drug Interaction

Details coming soon

Disease Interaction

Details coming soon

Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage

Details coming soon

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.